title: [2/2 The other biotherapies].
authors: CHU Besançon.
authors: Cécile
authors: C
authors: Fournel
authors: Mehdi
authors: M
authors: Medjoub
authors: Samuel
authors: S
authors: Limat
authors: Marie-Christine
authors: MC
authors: Woronoff-Lemsi
mesh_terms: D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D004347:Drug Interactions; D016903:Drug Monitoring; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D017053:Infection Control; D016023:Integrins / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D007378:Interleukins / Q000627:therapeutic use; D000069442:Natalizumab; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018796:Immunoconjugates; D007155:Immunologic Factors; D016023:Integrins; D053590:Interleukin 1 Receptor Antagonist Protein; D007378:Interleukins; D000069442:Natalizumab; D000069283:Rituximab; D000069594:Abatacept; C502936:tocilizumab